Enhancing Oncolytic Rhabdovirus Infection With Sunitinib In An IFN Responsive Tumour Model

Simple item page
atmire.migration.oldid4344
dc.contributor.advisorMahoney, Douglas
dc.contributor.authorDastidar, Himika
dc.contributor.committeememberMorris, Don
dc.contributor.committeememberMcCafferty, Donna-Marie
dc.date.accessioned2016-05-04T20:55:03Z
dc.date.available2016-05-04T20:55:03Z
dc.date.issued2016
dc.date.submitted2016en
dc.description.abstractOncolytic virus (OV) therapy for cancer is an emerging biotherapeutic strategy that employs replicating viruses to selectively infect and kill cancer cells. While promising, host innate immunity, namely type I IFN signaling, remains a barrier to OV therapy as it eliminates the virus before it spreads efficiently through the tumour. Sunitinib (Su), a receptor tyrosine kinase inhibitor, was recently shown to enhance OV infection by inhibiting IFN signaling in tumour cells. We therefore hypothesized that Su might enhance oncolytic rhabdovirus (ORV) infection in tumours. Indeed, Su treatment improved ORV productivity, tumour regression and overall survival in an IFN responsive tumour model. Su reduced the number and function of IFN producing myeloid cells such as cDCs and MΦ and thereby improved tumour infection with ORV. Collectively, our findings provide further support for the clinical evaluation of Su/ORV co-therapy in OV refractory tumors.en_US
dc.identifier.citationDastidar, H. (2016). Enhancing Oncolytic Rhabdovirus Infection With Sunitinib In An IFN Responsive Tumour Model (Master's thesis, University of Calgary, Calgary, Canada). Retrieved from https://prism.ucalgary.ca. doi:10.11575/PRISM/25906en_US
dc.identifier.doihttp://dx.doi.org/10.11575/PRISM/25906
dc.identifier.urihttp://hdl.handle.net/11023/2967
dc.language.isoeng
dc.publisher.facultyGraduate Studies
dc.publisher.institutionUniversity of Calgaryen
dc.publisher.placeCalgaryen
dc.rightsUniversity of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission.
dc.subjectVirology
dc.subjectImmunology
dc.subjectOncology
dc.subject.classificationVirologyen_US
dc.subject.classificationTumor Immunologyen_US
dc.subject.classificationOncolytic Virotherapyen_US
dc.subject.classificationOncolytic Immunotherapyen_US
dc.subject.classificationSunitiniben_US
dc.titleEnhancing Oncolytic Rhabdovirus Infection With Sunitinib In An IFN Responsive Tumour Model
dc.typemaster thesis
thesis.degree.disciplineMicrobiology & Infectious Diseases
thesis.degree.grantorUniversity of Calgary
thesis.degree.nameMaster of Science (MSc)
ucalgary.item.requestcopytrue
Files
Collections
Open Theses and Dissertations